Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 8/20 | 0.42 |
| ▸ | USP5 | P45974 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.34 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | SRC | P12931 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1897092 | 1.00 | P2RX7 (0.42) | P2RX7USP5LMNAHTTKDM4E | |
| SCHEMBL1897096 | 1.00 | P2RX7 (0.42) | P2RX7USP5LMNAHTTKDM4E | |
| SCHEMBL1590034 | 0.84 | PARP1 (0.48) | P2RX7USP5LMNAHTTKDM4E | |
| SCHEMBL12668523 | 0.84 | P2RX7 (0.45) | P2RX7USP5LMNAHTTKDM4E | |
| SCHEMBL1589819 | 0.84 | PARP1 (0.48) | P2RX7USP5LMNAHTTKDM4E | |
| SCHEMBL1589818 | 0.84 | PARP1 (0.48) | P2RX7USP5LMNAHTTKDM4E | |
| SCHEMBL12668525 | 0.84 | P2RX7 (0.45) | P2RX7USP5LMNAHTTKDM4E | |
| SCHEMBL15869588 | 0.82 | P2RX7 (0.41) | P2RX7USP5LMNAHTTKDM4E | |
| SCHEMBL5135477 | 0.82 | P2RX7 (0.41) | P2RX7USP5LMNAHTTKDM4E | |
| SCHEMBL12725533 | 0.81 | P2RX7 (0.41) | P2RX7USP5LMNAHTTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1937643-B1 | BICYCLOHETEROARYL COMPOUNDS AS P2X7 MODULATORS AND USES THEREOF | SECOND GENOME INC (US) | 2016-07-13 | — | — | EP | disclosed |
| EP-1937643-B1 | BICYCLOHETEROARYL COMPOUNDS AS P2X7 MODULATORS AND USES THEREOF | SECOND GENOME INC (US) | 2016-07-13 | — | — | EP | disclosed |
| US-8779144-B2 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | EVOTEC (US) INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-8779144-B2 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | EVOTEC (US) INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-8779144-B2 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | EVOTEC (US) INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-20110118287-A1 | Bicycloheteroaryl Compounds As P2X7 Modulators and Uses Thereof | RENOVIS, INC. (US) | 2011-05-19 | — | — | US | disclosed |
| EP-1937643-A2 | BICYCLOHETEROARYL COMPOUNDS AS P2X7 MODULATORS AND USES THEREOF | Renovis, Inc. (US) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007109160-A9 | BICYCLOHETEROARYL COMPOUNDS AS P2X7 MODULATORS AND USES THEREOF | RENOVIS INC (US) | 2007-11-15 | — | — | WO | disclosed |
| WO-2007109160-A9 | BICYCLOHETEROARYL COMPOUNDS AS P2X7 MODULATORS AND USES THEREOF | RENOVIS INC (US) | 2007-11-15 | — | — | WO | disclosed |
| WO-2007109160-A2 | BICYCLOHETEROARYL COMPOUNDS AS P2X7 MODULATORS AND USES THEREOF | RENOVIS, INC. (US) | 2007-09-27 | — | — | WO | disclosed |
| WO-2007109160-A2 | BICYCLOHETEROARYL COMPOUNDS AS P2X7 MODULATORS AND USES THEREOF | RENOVIS, INC. (US) | 2007-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118287-A1 | Bicycloheteroaryl Compounds As P2X7 Modulators and Uses Thereof | P2RX7, P2RX3, P2RX1 | P2RX7 1/4885USP5 4794/4885LMNA 1549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.